SLx-2101
As of the edition of 20 October 2026, SLx-2101 is a drug known only by a code name: went quiet in 2008; acts on PDE5A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2008
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of SLx-2101.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | O76074 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Response Pharmaceuticals | Lead sponsor of trials | 2007 to now |
| Retension Pharmaceuticals | Lead sponsor of trials | 2007 to now |